378 related articles for article (PubMed ID: 32308773)
1. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
2. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.
Lee W; Lee JH; Jun S; Lee JH; Bang D
Sci Rep; 2018 Aug; 8(1):11879. PubMed ID: 30089886
[TBL] [Abstract][Full Text] [Related]
3. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS.
Liu J; Sun M; Cho KB; Gao X; Guo B
Pharmacol Res; 2021 Feb; 164():105304. PubMed ID: 33202255
[TBL] [Abstract][Full Text] [Related]
4. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
[TBL] [Abstract][Full Text] [Related]
5. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.
Koo T; Yoon AR; Cho HY; Bae S; Yun CO; Kim JS
Nucleic Acids Res; 2017 Jul; 45(13):7897-7908. PubMed ID: 28575452
[TBL] [Abstract][Full Text] [Related]
6. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
7. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
[TBL] [Abstract][Full Text] [Related]
8. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
10. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
Budagyan K; Chernoff J
Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
[TBL] [Abstract][Full Text] [Related]
11. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.
Sinha S; Barbosa K; Cheng K; Leiserson MDM; Jain P; Deshpande A; Wilson DM; Ryan BM; Luo J; Ronai ZA; Lee JS; Deshpande AJ; Ruppin E
Nat Commun; 2021 Nov; 12(1):6512. PubMed ID: 34764240
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
13. Targeting mutant
Kim W; Lee S; Kim HS; Song M; Cha YH; Kim YH; Shin J; Lee ES; Joo Y; Song JJ; Choi EJ; Choi JW; Lee J; Kang M; Yook JI; Lee MG; Kim YS; Paik S; Kim HH
Genome Res; 2018 Jan; 28(3):374-82. PubMed ID: 29326299
[No Abstract] [Full Text] [Related]
14. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
Tsukumo Y; Naito M; Suzuki T
PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.
Yau EH; Kummetha IR; Lichinchi G; Tang R; Zhang Y; Rana TM
Cancer Res; 2017 Nov; 77(22):6330-6339. PubMed ID: 28954733
[TBL] [Abstract][Full Text] [Related]
16. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
17. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
18. CRISPR and KRAS: a match yet to be made.
Bender G; Fahrioglu Yamaci R; Taneri B
J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]